论文部分内容阅读
目的探讨经肝动脉化疗栓塞联合替吉奥治疗中晚期肝细胞癌的临床疗效及安全性。方法 68例中晚期肝细胞癌患者,根据不同治疗方案分为观察组和对照组,各34例。对照组给予经肝动脉化疗栓塞,观察组在此基础上联合替吉奥治疗。对比两组治疗6个月临床疗效、不良反应发生及2年内生存情况。结果观察组治疗总有效率为61.76%,疾病控制率为85.29%,均显著高于对照组的32.35%与52.94%(P<0.05);观察组1年内生存率为76.47%,2年内生存率为50.00%,均分别高于对照组的50.00%与26.47%,差异有统计学意义(P<0.05)。结论在经肝动脉化疗栓塞基础上加用替吉奥治疗中晚期肝细胞癌,临床效果显著,可有效提高患者生存率,且具有一定安全性。
Objective To investigate the clinical efficacy and safety of transcatheter arterial chemoembolization combined with tigiao in the treatment of advanced hepatocellular carcinoma. Methods Sixty-eight patients with advanced hepatocellular carcinoma were divided into observation group and control group according to different treatment regimens, 34 cases in each. The control group was given transcatheter arterial chemoembolization. On the basis of this, the observation group was treated with treatment of Giovanni. The clinical efficacy, adverse reactions and survival within two years were compared between the two groups for 6 months. Results The total effective rate of the observation group was 61.76% and the disease control rate was 85.29%, which were significantly higher than those of the control group (32.35% vs 52.94%, P <0.05). The 1-year survival rate was 76.47% (50.00%) were higher than that of the control group (50.00% vs. 26.47%, respectively), the difference was statistically significant (P <0.05). Conclusions The addition of TIGO to advanced hepatocellular carcinoma on the basis of transcatheter arterial chemoembolization has significant clinical effect, which can effectively improve the survival rate of patients and has certain safety.